

Press Release

Contact:

INVESTOR RELATIONS
KEDAR UPADHYE
kedaru@drreddys.com
(Ph: +91-40-66834297)

MEDIA RELATIONS
CALVIN PRINTER
calvinprinter@drreddys.com
(Ph: +91-40- 49002121)

107 College Road East
Princeton, NJ 08540

www.promiuspharma.com

Dr. Reddy's Laboratories Ltd. and its U.S. subsidiary Promius Pharma™ LLC receive FDA approval for ZEMBRACE SymTouch™ (sumatriptan succinate) Injection for the acute treatment of migraines in adults

Princeton, N.J., January 29, 2016. Promius Pharma™, LLC, the U.S. subsidiary of India's Dr. Reddy's Laboratories (NYSE:RDY), announced today that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE SymTouch™ (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens. ZEMBRACE SymTouch is available as a prefilled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan, a selective 5-HT_{1B/1D} receptor agonist. The injection is intended to be given subcutaneously. Safety and effectiveness in pediatric patients have not been established. ZEMBRACE SymTouch injection is not recommended for use in patients younger than 18 years of age.

"Promius Pharma is pleased to have received FDA approval for ZEMBRACE SymTouch," said Raghav Chari, Head of Promius Pharma. "Today's approval is a major milestone for Promius Pharma, as ZEMBRACE SymTouch is the first branded product in our central nervous system portfolio. Migraine affects millions of patients. Many of these patients have busy lives and quick pain relief is critical to help them manage through their daily routines. In many cases, migraine episodes are accompanied by severe nausea, making it difficult to swallow and retain pills. ZEMBRACE SymTouch is specifically designed for patients who may experience certain migraine episodes but for whom a pill may not be the right option."

"Promius Pharma is a significant driver of long-term growth for Dr. Reddy's and we are excited about this FDA approval. This marks a major milestone for the company as we bring innovative medicines to patients and physicians," said Dr. Reddy's Laboratories CEO and Co-Chairman, G.V. Prasad.

<http://www.zembrace.com>

-end-

For more information, please contact:

About Promius Pharma: Promius Pharma is a wholly owned subsidiary of Dr. Reddy's Laboratories, one of largest and most respected pharmaceutical companies in the world. Our approach to product development relies heavily on converting deep insights gained from patients and physicians combined with strong collaborations with KOLs throughout the development continuum into highly innovative product concepts. Current R&D pipeline and commercialized products address the needs of patients with dermatological and neurological conditions. The company has successfully established a robust commercial infrastructure and leverages the extensive research and development capabilities available through its parent company. For more information, log on to www.promiuspharma.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.

Press Release

INVESTOR RELATIONS
KEDAR UPADHYE
kedaru@drreddys.com
(Ph: +91-40-66834297)

Contact:

MEDIA RELATIONS
CALVIN PRINTER
calvinprinter@drreddys.com
(Ph: +91-40- 49002121)

Investor Relations, USA

Ashish Girotra (USA)
ashishg@drreddys.com
+1 6093759805

Media Relations, USA

Lori McCreary (USA)
lmccreary@drreddys.com
+1 6093752995

About Promius Pharma: Promius Pharma is a wholly owned subsidiary of Dr. Reddy's Laboratories, one of largest and most respected pharmaceutical companies in the world. Our approach to product development relies heavily on converting deep insights gained from patients and physicians combined with strong collaborations with KOLs throughout the development continuum into highly innovative product concepts. Current R&D pipeline and commercialized products address the needs of patients with dermatological and neurological conditions. The company has successfully established a robust commercial infrastructure and leverages the extensive research and development capabilities available through its parent company. For more information, log on to www.promiuspharma.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.